Academic Journal
Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.
| Τίτλος: | Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation. |
|---|---|
| Συγγραφείς: | Perciani CT; Department of Immunology, University of Toronto, Toronto, Ontario, Canada., Farah B; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya., Kaul R; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; University Health Network, Toronto, Ontario, Canada., Ostrowski MA; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Keenan Research Center, St. Michael's Hospital, Toronto, Ontario, Canada., Mahmud SM; Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada., Anzala O; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya., Jaoko W; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya., MacDonald KS; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Section of Infectious Diseases, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. |
| Συλλογικό Έργο: | KAVI-ICR Team |
| Πηγή: | The Journal of clinical investigation [J Clin Invest] 2019 Feb 01; Vol. 129 (2), pp. 875-886. Date of Electronic Publication: 2019 Jan 22. |
| Τύπος έκδοσης: | Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Imprint Name(s): | Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation Original Publication: New Haven [etc.] American Society for Clinical Investigation. |
| Ιατρικοί όροι (MeSH): | AIDS Vaccines*/administration & dosage , AIDS Vaccines*/immunology , Herpesvirus 3, Human*/genetics , Herpesvirus 3, Human*/immunology , Virus Activation*/drug effects , Virus Activation*/immunology, CD4-Positive T-Lymphocytes/*immunology , HIV-1/*physiology, CD4-Positive T-Lymphocytes/pathology ; CD4-Positive T-Lymphocytes/virology ; Vaccines, Attenuated/administration & dosage ; Vaccines, Attenuated/immunology ; Varicella Zoster Virus Infection/immunology ; Varicella Zoster Virus Infection/pathology ; Varicella Zoster Virus Infection/prevention & control ; Adult ; Female ; Humans ; Kenya |
| Περίληψη: | Background: Varicella-zoster virus (VZV) is under consideration as a promising recombinant viral vector to deliver foreign antigens including HIV. However, new vectors have come under increased scrutiny, since trials with adenovirus serotype 5-vectored (Ad5-vectored) HIV vaccine demonstrated increased HIV risk in individuals with pre-immunity to the vector that was thought to be associated with mucosal immune activation (IA). Therefore, given the prospect of developing an HIV/VZV chimeric vaccine, it is particularly important to define the impact of VZV vaccination on IA. Methods: Healthy VZV-seropositive Kenyan women (n = 44) were immunized with high-dose live attenuated VZV vaccine, and we assessed the expression on CD4+ T cells isolated from blood, cervix, and rectum of IA markers including CD38 and HLA-DR and of markers of cell migration and tissue retention, as well as the concentration of genital and intestinal cytokines. A delayed-start group (n = 22) was used to control for natural variations in these parameters. Results: Although immunogenic, VZV vaccination did not result in significant difference in the frequency of cervical activated (HLA-DR+CD38+) CD4+ T cells (median 1.61%, IQR 0.93%-2.76%) at 12 weeks after vaccination when compared with baseline (median 1.58%, IQR 0.75%-3.04%), the primary outcome for this study. VZV vaccination also had no measurable effect on any of the IA parameters at 4, 8, and 12 weeks after vaccination. Conclusion: This study provides the first evidence to our knowledge about the effects of VZV vaccination on human mucosal IA status and supports further evaluation of VZV as a potential vector for an HIV vaccine. Trial Registration: ClinicalTrials.gov NCT02514018. Funding: Primary support from the Canadian Institutes for Health Research (CIHR). For other sources, see Acknowledgments. |
| References: | Nature. 2002 Jan 17;415(6869):331-5. (PMID: 11797011) J Infect Dis. 2008 Mar 15;197(6):825-35. (PMID: 18419349) N Engl J Med. 2013 Nov 28;369(22):2083-92. (PMID: 24099601) J Infect Dis. 2014 Jul 15;210(2):319-29. (PMID: 24421257) J Virol. 2005 Oct;79(19):12321-31. (PMID: 16160159) Lancet Infect Dis. 2008 Aug;8(8):490-7. (PMID: 18652995) Nat Med. 2014 Dec;20(12):1397-400. (PMID: 25419708) J Virol. 2010 Mar;84(6):2996-3003. (PMID: 20042509) J Med Virol. 2001 Jun;64(2):89-95. (PMID: 11360239) Mucosal Immunol. 2016 Jan;9(1):1-12. (PMID: 25872482) Immunity. 2007 Feb;26(2):257-70. (PMID: 17306567) J Infect Dis. 1992 Jan;165(1):119-26. (PMID: 1309369) AIDS Res Hum Retroviruses. 2006 Mar;22(3):255-61. (PMID: 16545012) J Infect Dis. 2018 Mar 13;217(7):1055-1059. (PMID: 29409017) J Infect Dis. 2012 Jul 15;206(2):258-66. (PMID: 22561365) Sex Transm Infect. 2014 Dec;90(8):580-7. (PMID: 25107710) J Virol. 2011 Oct;85(19):10189-200. (PMID: 21813616) PLoS One. 2018 Feb 8;13(2):e0192482. (PMID: 29420608) Nat Med. 2009 Mar;15(3):293-9. (PMID: 19219024) J Reprod Immunol. 2015 Aug;110:14-21. (PMID: 25956139) Nature. 2011 May 26;473(7348):523-7. (PMID: 21562493) Clin Microbiol Infect. 2013 May;19(5):E245-51. (PMID: 23331898) Nature. 2013 Oct 3;502(7469):100-4. (PMID: 24025770) J Infect Dis. 2011 Feb 1;203(3):312-5. (PMID: 21208922) BMJ Open. 2017 Sep 21;7(9):e017391. (PMID: 28939581) Lancet Infect Dis. 2014 May;14(5):388-96. (PMID: 24560541) JCI Insight. 2017 Apr 6;2(7):e91963. (PMID: 28405623) Mucosal Immunol. 2012 May;5(3):277-87. (PMID: 22318497) J Clin Microbiol. 1991 Feb;29(2):297-301. (PMID: 1706728) J Clin Invest. 2018 Oct 1;128(10):4429-4440. (PMID: 30024861) Retrovirology. 2006 Jun 22;3:35. (PMID: 16792805) J Clin Invest. 2014 Jul;124(7):3147-58. (PMID: 24911151) Sci Transl Med. 2018 Jan 24;10(425):. (PMID: 29367348) Adv Virol. 2013;2013:219439. (PMID: 23843791) Immunity. 2017 Jan 17;46(1):29-37. (PMID: 28087240) J Virol. 2007 Mar;81(6):2950-6. (PMID: 17192313) Mucosal Immunol. 2010 May;3(3):280-90. (PMID: 20147895) AIDS. 2015 Feb 20;29(4):395-400. (PMID: 25630039) PLoS One. 2014 Jul 07;9(7):e101920. (PMID: 25000587) EMBO J. 1990 May;9(5):1551-60. (PMID: 2184033) Clin Infect Dis. 2015 Jul 15;61(2):260-9. (PMID: 25900168) Am Fam Physician. 2000 Sep 1;62(5):1095-104. (PMID: 10997533) Expert Opin Biol Ther. 2004 Feb;4(2):199-216. (PMID: 14998778) Curr Opin HIV AIDS. 2010 Sep;5(5):357-61. (PMID: 20978374) PLoS Pathog. 2018 Feb 23;14(2):e1006888. (PMID: 29474461) Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13439-44. (PMID: 25197078) Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):518-23. (PMID: 25550504) Mucosal Immunol. 2018 May;11(3):932-946. (PMID: 29346349) Immunity. 2015 May 19;42(5):965-76. (PMID: 25992865) J Virol. 2012 Apr;86(7):3626-34. (PMID: 22258257) N Engl J Med. 2005 Jun 2;352(22):2271-84. (PMID: 15930418) J Virol. 2014 Aug;88(15):8468-78. (PMID: 24829340) Nat Med. 2018 May;24(4):491-496. (PMID: 29480895) J Infect Dis. 2018 Sep 8;218(8):1210-1218. (PMID: 29800309) Lancet. 2008 Nov 29;372(9653):1881-1893. (PMID: 19012954) Microbiol Immunol. 2013 Oct;57(10):704-14. (PMID: 23905963) J Virol. 2005 Dec;79(24):15556-66. (PMID: 16306626) J Infect Dis. 2008 Mar 1;197 Suppl 2:S58-60. (PMID: 18419410) J Infect Dis. 2002 Jan 1;185(1):45-52. (PMID: 11756980) Sex Transm Infect. 2016 May;92(3):186-93. (PMID: 26511781) Nature. 2009 Apr 23;458(7241):1034-8. (PMID: 19262509) Nature. 2010 Mar 11;464(7286):217-23. (PMID: 20220840) Annu Rev Med. 2011;62:127-39. (PMID: 21054171) Science. 2014 Apr 4;344(6179):49-51. (PMID: 24700849) Science. 2016 Oct 14;354(6309):197-202. (PMID: 27738167) Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13026-31. (PMID: 15326293) JCI Insight. 2017 Apr 6;2(7):e88533. (PMID: 28405607) |
| Grant Information: | THA-11960 Canada CIHR |
| Contributed Indexing: | Keywords: AIDS vaccine; AIDS/HIV; Cytokines; T cells; Vaccines |
| Molecular Sequence: | ClinicalTrials.gov NCT02514018 |
| Substance Nomenclature: | 0 (AIDS Vaccines) 0 (Vaccines, Attenuated) |
| Entry Date(s): | Date Created: 20181205 Date Completed: 20191216 Latest Revision: 20200309 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6355215 |
| DOI: | 10.1172/JCI124473 |
| PMID: | 30511963 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!